GSK plc (NYSE:GSK) Position Boosted by San Luis Wealth Advisors LLC

San Luis Wealth Advisors LLC increased its holdings in GSK plc (NYSE:GSK) by 37.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,968 shares of the pharmaceutical company’s stock after purchasing an additional 6,031 shares during the quarter. San Luis Wealth Advisors LLC’s holdings in GSK were worth $743,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in GSK. Eastern Bank bought a new position in shares of GSK in the third quarter valued at $26,000. Sunbelt Securities Inc. grew its holdings in shares of GSK by 73.8% in the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Concord Wealth Partners raised its position in shares of GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 547 shares during the period. ST Germain D J Co. Inc. lifted its holdings in shares of GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new position in shares of GSK in the 2nd quarter valued at $37,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK opened at $32.12 on Wednesday. The company has a market capitalization of $66.57 billion, a PE ratio of 20.86, a PEG ratio of 1.52 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company’s 50 day moving average price is $34.20 and its 200 day moving average price is $38.08. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.89%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s payout ratio is currently 95.45%.

Analysts Set New Price Targets

GSK has been the topic of several recent analyst reports. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.